Arzerra(tm) (ofatumumab) Granted Priority Review by FDA

Summary: the US FDA has Accepted the Biologics License Application for ofatumumab

Related Quotes

Symbol	Price	Change
GEN	0.00	0.00

{"s" : "gen","k" : "c10,l10,p20,t10","o" : "","j" : ""}

COPENHAGEN, Denmark, April 3, 2009 (GLOBE NEWSWIRE) -- Genmab today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Arzerra(tm) (ofatumumab) to treat patients whose chronic lymphocytic leukemia (CLL) is resistant (refractory) to previous therapies and has granted ofatumumab priority review status.

Under priority review, the FDA sets the target date for a decision from regulators at six months, rather than the standard 10 month review. If approved, ofatumumab would be the first monoclonal antibody targeted to CD20 available for this patient population. In addition, the FDA has granted ofatumumab orphan designation for the treatment of CLL. The BLA was submitted on January 30, 2009.

``We are pleased that the ofatumumab BLA has been accepted for review by the FDA and look forward to the outcome of the review process,'' said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

The acceptance of the BLA will trigger a milestone payment from GSK to Genmab of DKK 87 million (approximately $15 million). In addition, Genmab will also receive a one-time payment of $4.5 million from GSK in exchange for terminating its option to co-promote Arzerra(tm). In December 2008, GSK and Genmab amended their initial agreement and GSK now has exclusive global commercialization rights to Arzerra for all potential indications.

About ofatumumab

Ofatumumab is a novel, investigational, fully human monoclonal antibody that targets a membrane-proximal (close to the cell surface) small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule of B-cells. This epitope is different from the binding sites targeted by other CD20 antibodies currently available. The CD20 molecule is a key target in CLL therapy because it is expressed on most B-cells in CLL patients.

Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved in any country.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's world class discovery, development and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This Stock Exchange Release contains forward looking statements. The words ``believe'', ``expect'', ``anticipate'', ``intend'' and ``plan'' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section ``Risk Management'' in Genmab's Annual Report, which is available on http://www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Stock Exchange Release nor to confirm such statements in relation to actual results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r);HuMax-EGFr(tm); HuMax-IL8(tm); HuMax-TAC(tm); HuMax-HepC(tm); HuMax-CD38(tm); HuMax-CD32b(tm); HuMax-TF(tm); HuMax-Her2(tm); HuMax-VEGF(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(tm) is a trademark of GlaxoSmithKline.

Stock Exchange Release no. 12/2009

          Genmab A/S
          Helle Husted, Vice President, Investor Relations
          +45 33 44 77 30
          M: +45 25 27 47 13
          h.husted@genmab.com